Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
An announcement from Pulse Biosciences ( (PLSE) ) is now available.
On December 9, 2025, Pulse Biosciences announced a research collaboration with The University of Texas MD Anderson Cancer Center to explore the use of its nPulse™ Vybrance™ Percutaneous Electrode System for treating thyroid cancers. The FDA has approved the Investigational Device Exemption for this first-in-human clinical feasibility study, which will begin in early 2026, involving 30 subjects across two sites. This collaboration aims to assess the safety and effectiveness of nPulse technology in treating papillary thyroid microcarcinoma, with ongoing preclinical studies on anaplastic thyroid carcinoma, a particularly deadly cancer. The nonthermal mechanism of nsPFA energy is highlighted for its potential to minimize scarring and damage to surrounding structures, positioning it as a promising treatment for both benign and malignant thyroid tumors.
The most recent analyst rating on (PLSE) stock is a Buy with a $22.00 price target. To see the full list of analyst forecasts on Pulse Biosciences stock, see the PLSE Stock Forecast page.
Spark’s Take on PLSE Stock
According to Spark, TipRanks’ AI Analyst, PLSE is a Neutral.
Pulse Biosciences receives a low overall score due to persistent financial challenges such as continuous losses and cash burn. While technical indicators show some positive momentum, the valuation remains unattractive due to negative earnings. The earnings call provided a balanced view with notable advancements in technology and strengthened finances, but increased operational costs remain a concern. The CFO appointment is a positive strategic move but does not significantly affect the overall score.
To see Spark’s full report on PLSE stock, click here.
More about Pulse Biosciences
Pulse Biosciences is a novel bioelectric medicine company focused on health innovation, utilizing its proprietary nPulse™ technology to deliver nanosecond pulses of electrical energy for non-thermal cellular clearance. The company is developing this technology for applications such as atrial fibrillation treatment and surgical soft tissue ablation, aiming to improve healthcare outcomes for patients and providers.
Average Trading Volume: 190,361
Technical Sentiment Signal: Sell
Current Market Cap: $899.3M
Find detailed analytics on PLSE stock on TipRanks’ Stock Analysis page.